CCL20增强HBsAg的免疫应答效应  

CCL20 enhances immune response of HBsAg in C57BL/6 mice

作　　者：邵先安[1] 赵阳[1] 谷旻[1] 王勇[1] 陈芝河[1] 

机构地区：[1]解放军第123医院,安徽蚌埠233015

出　　处：《中国实验诊断学》2009年第8期1016-1018,共3页Chinese Journal of Laboratory Diagnosis

基　　金：南京军区卫生专业人才培养"122工程"资助项目

摘　　要：目的为探讨CCL20对HBsAg介导的免疫应答是否具有增强作用,为CCL20这一细胞因子作为新型乙肝制剂的应用研究提供理论依据。方法采用基因重组技术,构建趋化因子CCL20和表面抗原(HBsAg)的真核表达载体,将重组载体用肌肉免疫的方式分别注射正常的C57BL/6小鼠,通过ELISA方法检测C57BL/6小鼠的抗-HBs抗体水平、细胞增殖情况。结果用CCL20/HBsAg真核表达质粒共注射免疫后,100%小鼠能在第4、6周检测到教高效价的抗-HBs抗体,持续时间长达10周;同时,CCL20增强了HBsAg的细胞免疫反应。结论CCL20能增强小鼠针对HBsAg的体液和细胞免疫应答反应,这将为新型乙肝特异性免疫治疗应用研究提供依据。Objective To investigate the feasibility and functional mechanism of CCL20/HBsAg DNA vaccine as prevention and therapeutic vaccine for hepatitis B. Methods CCL20 and HBsAg eukaryon expression vector was constructed by using DNA recombinant technology. Normal C57BL/6 mice were injected from muscle. The antibody of anti-HBs was detected by ELISA. Results Anti- HBs antibody can be detected at the 4th and 6th week,which Can maintain up to 10 wk after the injection of immune normal mice with eukaryotic expressive plasmid. Conclusion Humoral and cellular immunity can be enhanced after the injection of HBsAg plus CCL20 DNA vaccine. All these provide experimental fotmdafion for the further research of therapeutic CHB patient reagents.

关 键 词：CCL20 HBSAG 增强 免疫应答 

分 类 号：R392.1[医药卫生—免疫学]